Oral Lichen Planus Clinical Trial
Official title:
The APOLP Trial: A Single-Center, Randomized, 16 Weeks, Explanatory, Parallel-Group, Superiority, Blinded, Placebo-Controlled, Clinical Trial of Apremilast Use in Oral Lichen Planus
Apremilast for the management of oral lichen planus.
Oral lichen planus (OLP) affects approximately 1.27% of the general population. Inflammatory
responses constitute a major component of OLP pathogenesis where targeted therapies play an
important role in managing this condition. Apremilast is a new well-tolerated and relatively
safe anti-inflammatory therapy that has been approved for managing psoriasis and psoriatic
arthritis. Given its safer profile, Apremilast may ameliorate inflammatory responses in
clinically active OLP without the experience of serious adverse events associated with other
systemic immunosuppressive therapies used to treat OLP. The plan is to conduct a
single-center, explanatory, randomized, 16 weeks, parallel group, superiority, blinded,
placebo-controlled, clinical trial.
The main objective is treatment success assessment. Other objectives include exploring the
efficacy of Apremilast in clinically active OLP adult patients considered for systemic
treatment and failed topical corticosteroid therapy. It is hypothesized that Apremilast will
induce more treatment success as compared to placebo in patients who failed the standard
treatment of topical corticosteroids.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05997173 -
The Regulatory Role of Immune Response in Oral Lichen Planus
|
||
| Completed |
NCT02443311 -
Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus
|
Phase 4 | |
| Completed |
NCT00484250 -
Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other
|
Phase 2 | |
| Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
| Completed |
NCT04193748 -
Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial)
|
Phase 4 | |
| Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
| Recruiting |
NCT06135805 -
Impact of Fluocinonide 0,05% in Oral Lichen Planus
|
N/A | |
| Completed |
NCT04289233 -
Molecular & Cellular Characterisation of Oral Lichen Planus
|
||
| Completed |
NCT04293718 -
Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
|
||
| Completed |
NCT00525421 -
A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus
|
Phase 2 | |
| Not yet recruiting |
NCT04091698 -
Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial
|
Phase 1 | |
| Completed |
NCT03386643 -
Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus
|
Phase 2 | |
| Completed |
NCT05730855 -
Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
|
||
| Completed |
NCT03257228 -
The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)
|
N/A | |
| Recruiting |
NCT03026478 -
Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus
|
Phase 2 | |
| Completed |
NCT02834520 -
Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus
|
N/A | |
| Completed |
NCT02858297 -
Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus
|
Phase 4 | |
| Completed |
NCT02106468 -
The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus
|
Phase 2 | |
| Recruiting |
NCT00737854 -
Free Soft Tissue Graft in Treatment of Oral Lichen Planus
|
Phase 1 | |
| Completed |
NCT00111072 -
Dexamethasone to Treat Oral Lichen Planus
|
Phase 2 |